When glioblastoma (GBM) returns after initial treatment, one of the hardest questions is whether radiation can be used again. Re-irradiation for recurrent glioblastoma - delivering a new course of radiation to a brain that has already received the standard 60 Gy dose - is not a universal protocol, but it is increasingly used at specialist centers worldwide. This guide explains who may be eligible, what the risks are, how the decision is weighed, and how patients from outside the US or Europe can access expert re-irradiation programs.
What Is Re-Irradiation, and How Does It Differ From the First Course?
During initial GBM treatment, radiation is typically delivered over six weeks as 60 Gy in 30 daily fractions, alongside temozolomide chemotherapy. This is the Stupp protocol - you can read how each phase unfolds in our article on the Stupp protocol for glioblastoma, phase by phase.
Re-irradiation means delivering radiation to the tumor site - or a new area of tumor growth - a second time. Because the brain has already received a significant dose, the main challenge is giving enough radiation to affect the tumor while keeping the total cumulative exposure to normal brain tissue within safe limits. Most centers therefore use tightly focused, short-course techniques rather than a second full six-week course.
Who Is Eligible for Re-Irradiation?
Most programs consider re-irradiation for patients with confirmed GBM recurrence who have a Karnofsky Performance Status of at least 60 to 70, adequate time since their first radiation course (typically at least 6 months), a focal and localized recurrence pattern, and no major decline in neurological function. Tumor size, proximity to sensitive brain structures, and prior radiation dose records all affect the final decision.
Eligibility criteria vary by center and technique, but published trial data and retrospective series consistently highlight these factors:
- Performance status. Most protocols require a Karnofsky Performance Status (KPS) of at least 60. KPS is a scale from 0 to 100 where higher scores reflect greater independence. A KPS below 60 generally signals that the risks of re-irradiation outweigh its likely benefit. A retrospective analysis from the National Cancer Institute identified KPS at re-irradiation as one of the strongest predictors of outcome.
- Interval since first radiation. Most centers require at least 6 months since the end of the first radiation course. Some programs set the bar at 8 months or longer. The waiting period allows normal brain tissue to recover and reduces the risk of cumulative toxicity.
- Recurrence pattern. Focal recurrence - a single distinct lesion returning in or near the original site - is generally a better candidate than widespread, multifocal, or leptomeningeal spread. Smaller lesions, typically under 4 cm in diameter, are associated with better response and lower toxicity risk. A systematic review and meta-analysis of re-irradiation for recurrent GBM found tumor volume at the time of re-irradiation to be a significant prognostic factor.
- Prior radiation dose and volume. The radiation planning team will review your original treatment records to calculate how much dose structures like the brainstem, optic chiasm, and hippocampus have already received. Each critical structure has a cumulative dose limit. If those limits are already close to being reached, safe re-irradiation may not be feasible or may require significant dose reduction.
- Molecular markers. Some centers factor MGMT methylation status into combined re-irradiation plus chemotherapy decisions. The role of MGMT in predicting response to radiation alone is less established, but it matters if temozolomide is added to the plan.
Not every patient who meets these criteria will receive re-irradiation. The decision goes through a multidisciplinary team and takes into account other available options - including repeat surgery, systemic chemotherapy, or a clinical trial.
How Do the Techniques Compare?
Re-irradiation is not one technique. Several approaches exist, each with different fractionation, dose distribution, and risk profiles. Your team will choose based on tumor size, location, available equipment, and your original treatment plan.
How do re-irradiation techniques differ for recurrent glioblastoma?
| Factor | Stereotactic Radiosurgery (SRS) | Hypofractionated SBRT | Proton Beam Re-RT |
|---|---|---|---|
| Best-suited tumor size | Small lesions, typically under 3-4 cm | Small to moderate lesions | Small to moderate; useful near sensitive brain structures |
| Typical fractionation | 1-5 high-dose fractions | Often 5-15 fractions (e.g., 30 Gy in 5) | Varies by center; often hypofractionated |
| Radiation necrosis risk | Moderate; higher with larger single-fraction doses | Reported at 7-13% in published cohorts at cumulative EQD2 doses of 102-130 Gy | May be lower due to Bragg-peak dose delivery; data still emerging |
| Availability | Widely available at specialist cancer centers | Widely available at specialist cancer centers | Specialized centers only; limited globally |
| Commonly combined with | Bevacizumab | Bevacizumab or temozolomide | Systemic therapy at center discretion |
Radiation necrosis risk figure cited from Bevacizumab combined with re-irradiation in recurrent glioblastoma (PMC, 2022). Fractionation schedule data from Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years of experience (PMC, 2024).
Hypofractionated stereotactic body radiotherapy (SBRT) is currently the most widely used approach for re-irradiation. The 12-year single-center experience cited above reported one-year overall survival of 46% and one-year progression-free survival of 35% following hypofractionated stereotactic re-irradiation. Proton beam re-irradiation is at an earlier stage of clinical evidence and is offered at only a small number of centers globally.
What Are the Main Risks?
Re-irradiation carries real risks. Understanding them clearly is part of making an informed decision.
Radiation necrosis is the most significant concern. This is brain tissue injury caused by cumulative radiation exposure. It can look almost identical to tumor regrowth on a standard MRI, which creates genuine diagnostic confusion. Distinguishing radiation necrosis from true tumor progression is a problem also familiar from pseudoprogression after initial treatment - our article on pseudoprogression in glioblastoma after chemoradiation explains how oncologists approach that challenge. Advanced imaging or, in some cases, a biopsy may be needed to separate the two.
Neurological worsening is another concern. Radiation to an already-treated brain can worsen cognitive function, fatigue, or focal deficits such as speech or motor difficulties. The risk is highest when re-irradiation overlaps significantly with previously treated brain regions or when the tumor is near eloquent cortex - regions responsible for language or movement.
Cerebral edema (swelling) may worsen during or after re-irradiation and your doctor usually manages it with corticosteroids such as dexamethasone. Long-term steroid use carries its own side effects, including elevated blood sugar, immune suppression, and muscle weakness, so managing steroid dose carefully matters.
How Does Bevacizumab Factor Into the Decision?
Bevacizumab - an anti-angiogenic drug that targets blood vessel growth - is frequently used alongside re-irradiation at recurrence. Two potential benefits drive this combination. First, bevacizumab may reduce radiation-related brain swelling and lower the risk of symptomatic radiation necrosis. Second, it has direct anti-tumor activity of its own. A 2025 meta-analysis comparing re-irradiation with and without bevacizumab found the combination was associated with improved progression-free survival compared to bevacizumab alone in patients with recurrent high-grade glioma.
Not all patients are candidates for bevacizumab. The drug is associated with blood pressure changes, wound healing risks, and thromboembolic events, so adding it to a re-irradiation plan requires its own eligibility review.
If your team is weighing re-irradiation after bevacizumab has already been tried and stopped working, the evidence base is limited. Some retrospective series have found that re-irradiation can still provide meaningful disease control in carefully selected patients in this scenario, particularly those with focal, small-volume recurrences and good performance status.
What Outcomes Can Patients Realistically Expect?
A multi-center retrospective study on re-irradiation for IDH-wildtype recurrent GBM in the bevacizumab and immunotherapy era found that carefully selected patients can achieve meaningful disease control, though outcomes vary considerably based on performance status, tumor volume, molecular markers, and whether systemic therapy is added. Patients with good KPS, small focal recurrences, and MGMT-methylated tumors tend to have the most favorable responses.
Be clear about what re-irradiation can do and what it cannot. It is not curative for recurrent GBM. The realistic aim is to slow tumor growth, preserve neurological function for as long as possible, and maintain quality of life. Patient selection is the most critical variable - which is why seeking re-irradiation through a high-volume center with dedicated neuro-oncology and radiation oncology teams matters.
International Access to Re-Irradiation
Access to re-irradiation is uneven globally. Advanced stereotactic platforms - including Gamma Knife, CyberKnife, and linear accelerator-based SBRT systems - are available at major cancer centers in India, Germany, South Korea, Thailand, Singapore, Turkey, and several other countries, as well as in the US, UK, and Australia. Proton beam re-irradiation is offered at far fewer centers and is still largely considered investigational for recurrent GBM.
If you are traveling from the GCC, Africa, South Asia, or elsewhere to access re-irradiation, the process typically involves several key steps. First, gather your original radiation planning data - specifically the DICOM RT plan files from your first course. A new treatment team cannot plan re-irradiation safely without knowing exactly what dose the brain has already received and where. Second, obtain a recent contrast-enhanced MRI, ideally within 4-6 weeks before your first consultation. Third, request a remote pre-travel consultation so the radiation oncologist can give a preliminary eligibility assessment before you commit to traveling and incurring costs.
Getting through this process from another country is demanding. If your current team has not raised re-irradiation as an option and you want to understand whether it applies to your case, you can consult the Art of Healing Cancer team on what your treatment options are before committing to a specific center or country.
For a broader framework for building your case at recurrence - including which records to gather and how to find specialized programs - see our guide to glioblastoma recurrence: building your second opinion case.
Active Clinical Trials
Clinical trials are evaluating re-irradiation combined with immunotherapy, radiosensitizing drugs, and other novel agents. The ClinicalTrials.gov listing for radiation therapy in recurrent brain tumors with prior radiotherapy gives a sense of how these studies are structured. Eligibility for most trials requires a minimum KPS, a defined interval since first radiation, and specific limits on prior bevacizumab use. Your neuro-oncologist or a specialist at a high-volume center can identify which open trials match your molecular profile and treatment history.
If you are ready to share your scans and reports for a remote clinical review, you can submit your case through the Glioblastoma Center patient-journey page before your next oncology appointment.
When to Talk to Your Doctor
Raise re-irradiation with your neuro-oncology team - or at a second-opinion appointment at a high-volume brain tumor center - if MRI has confirmed true tumor recurrence rather than pseudoprogression, the recurrence is focal and relatively small, at least 6 months have passed since your first radiation course ended, and your functional level remains good (KPS 60 or above). If re-irradiation has not been mentioned as an option, asking about it directly is reasonable - as is requesting a referral to a radiation oncologist with dedicated GBM expertise.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.